Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Published:2017-10 Issue:10103 Volume:390 Page:1664-1675
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Athauda Dilan,Maclagan Kate,Skene Simon S,Bajwa-Joseph Martha,Letchford Dawn,Chowdhury Kashfia,Hibbert Steve,Budnik Natalia,Zampedri Luca,Dickson John,Li Yazhou,Aviles-Olmos Iciar,Warner Thomas T,Limousin Patricia,Lees Andrew J,Greig Nigel H,Tebbs Susan,Foltynie Thomas

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. The ongoing pursuit of neuroprotective therapies in Parkinson disease;Athauda;Nat Rev Neurol,2014

2. Incretin-based therapies for type 2 diabetes mellitus;Lovshin;Nat Rev Endocrinol,2009

3. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas;Eng;J Biol Chem,1992

4. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions;Rampersaud;Neuropeptides,2012

5. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease;Harkavyi;J Neuroinflammation,2008

Cited by 520 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson’s Disease Patients;CNS & Neurological Disorders - Drug Targets;2024-05

2. Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches;CNS & Neurological Disorders - Drug Targets;2024-03

3. New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease;Neuropeptides;2024-02

4. Pharmacological interventions in human aging;Ageing Research Reviews;2024-02

5. Obesity drugs have another superpower: taming inflammation;Nature;2024-01-26